JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
reaffirmed their ‘Market Outperform' rating on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), while raising the price target to $143 from $86, implying an upside potential of over 200% from the current levels. This confidence follows the company's successful approval of Palsonify. The firm notes that Palsonify, an oral SST2 agonist designed for acromegalic adults who aren't fit for surgery, receives a broad label without any safety red flags, highlighting not only the rapidity of response but also improvement in symptom severity. While JMP had a price guidance of $125,000, the drug is sold at a price of $290,000 annually, which is significantly higher than the projected amount. Is Crinetics Pharmaceuticals Inc. (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts? That's not it. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is seizing every possible opportunity for expansion. This includes a Phase 3 study for carcinoid syndrome, along with two Phase 3 trials fo
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing TumorsGlobeNewswire
- Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid SyndromeGlobeNewswire
- Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Crinetics Pharmaceuticals (CRNX): Valuation in Focus After FDA Approval and Positive PALSONIFY Launch Momentum [Yahoo! Finance]Yahoo! Finance
- Why Crinetics Pharmaceuticals Stock Was Sliding on Friday [Yahoo! Finance]Yahoo! Finance
CRNX
Earnings
- 11/6/25 - Miss
CRNX
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/12/25 - Form SCHEDULE
- CRNX's page on the SEC website